Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix® (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC).

18 Mar 2011

Astellas to acquire all Maxygen's equity interests in Perseid for $76.0 million

Maxygen, Inc. today announced that Astellas Pharma Inc. has exercised its option to purchase all of Maxygen's equity interests in Perseid Therapeutics LLC at the current exercise price of $76.0 million.

17 Mar 2011

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

COMFORT-II, the second pivotal Phase III trial of Incyte Corporation's investigational Janus kinase inhibitor, ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis, when compared to best available therapy.

15 Mar 2011

Bayer receives FDA approval for Gadavist Injection

Bayer HealthCare Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration has approved Gadavist Injection, a macrocyclic gadolinium-based contrast agent, for intravenous use in diagnostic magnetic resonance imaging in adults and children to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.

14 Mar 2011

Erlotinib, Gefitinib effective in treating certain subset of advanced NSCLC patients

LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients.

11 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

Stemline Therapeutics, Inc. today announced that SL-401, the Company's lead compound, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

10 Mar 2011

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

ERYtech Pharma announces the early completion of the enrollment and safety follow-up a Phase II clinical trial for GRASPA. This open-labeled trial introduced GRASPA in a first-line treatment for Acute Lymphoblastic Leukemia in patients older than 55 years.

9 Mar 2011

Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO

Vermillion, a molecular diagnostics company, today announced the presentation of positive preliminary data from its collaboration with Johns Hopkins University School of Medicine to identify biomarkers that improve on the specificity of CA125 for the identification of malignant ovarian tumors.

9 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Multiple target therapy may treat HER2-positive breast cancers

Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center investigators.

9 Mar 2011

FDA approves Ipsen's application for Extended Dosing Interval of Somatuline Depot for acromegaly

Ipsen announced today that the Food and Drug Administration (FDA) has approved Ipsen's Prior Approval Supplement application for the Extended Dosing Interval of Somatuline® Depot for patients suffering from acromegaly.

9 Mar 2011

LRI announces 12 new research grants to drive innovation in lupus

The Lupus Research Institute today announced the award of 12 new research grants, building on its decade-long commitment to drive innovation and discover novel approaches to understand and treat one of the world's most confounding and elusive diseases - lupus.

9 Mar 2011

Study finds increase in oral tongue cancer incidence in young US white females

A UNC study released this week in the Journal of Clinical Oncology finds an increasing incidence of squamous cell carcinoma of the oral tongue in young white females in the United States over the last three decades.

9 Mar 2011

Study: Moderate drinking can reduce risk of dementia even among older adults

3202 German individuals attending general practitioners , who were free of dementia were studied at baseline, were followed up 1.5 years and 3 years later by means of structured clinical interviews including detailed assessment of current alcohol consumption and DSM-IV dementia diagnoses.

8 Mar 2011

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Eisai announced today that results from the global Phase III clinical study "EMBRACE" will be published online in The Lancet.

3 Mar 2011

Scientists find reprogramming-associated mutations in hiPSCs

Ordinary human cells reprogrammed as induced pluripotent stem cells may ultimately revolutionize personalized medicine by creating new and diverse therapies unique to individual patients.

3 Mar 2011

EpiCept: Positive outcome from Ceplene Phase III trial in patients with AML

EpiCept Corporation today announced the Company has identified a statistically significant survival benefit in a subgroup of Acute Myeloid Leukemia patients in its previous Phase III trial with Ceplene administered with low-dose interleukin-2.

3 Mar 2011

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

In 2010, Group drug sales grew 5.1% year-on-year - at constant currency - exceeding the objective set a year ago of 3.0% to 5.0%, fuelled notably by the sales of Specialty Care products throughout all the geographical regions where the Group operates.

2 Mar 2011

PAH closely related to bone marrow abnormalities

Results from a study published in Blood, the Journal of the American Society of Hematology reveal a close relationship between pulmonary arterial hypertension (PAH)-exceedingly high blood pressure in the arteries carrying blood from the heart to the lungs-and abnormalities of the blood-forming cells in the bone marrow (known as myeloid abnormalities).

1 Mar 2011

Hematology News and Research

Further Reading

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Astellas to acquire all Maxygen's equity interests in Perseid for $76.0 million

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

Bayer receives FDA approval for Gadavist Injection

Erlotinib, Gefitinib effective in treating certain subset of advanced NSCLC patients

Idera reports $6.0 million net loss for fourth quarter 2010

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Multiple target therapy may treat HER2-positive breast cancers

FDA approves Ipsen's application for Extended Dosing Interval of Somatuline Depot for acromegaly

LRI announces 12 new research grants to drive innovation in lupus

Study finds increase in oral tongue cancer incidence in young US white females

Study: Moderate drinking can reduce risk of dementia even among older adults

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Scientists find reprogramming-associated mutations in hiPSCs

EpiCept: Positive outcome from Ceplene Phase III trial in patients with AML

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

PAH closely related to bone marrow abnormalities

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News